Daily Stock List
TranSwitch Corp. (TXCC)
The Street, Wall Street Resources, StockEgg, PennyStockVille, PennyInvest, MadPennyStocks, BullRally, CoolPennyStocks, StockRich, and HotOTC reported earlier on TranSwitch Corp. (TXCC), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Shelton, Connecticut, TranSwitch Corp. designs, develops and supplies integrated circuit (IC) and intellectual property (IP) solutions. The Company's solutions provide core functionality for voice, data and video communications equipment for network, enterprise and customer premises applications. Their telecom products sell to original equipment manufacturers (OEMs) for use in an assortment of communications network equipment. Their interoperable connectivity solutions sell to OEMs for use in consumer electronics.
TranSwitch provides integrated multi-core network processor System-on-a-Chip (SoC) solutions and software solutions for Fixed, 3G and 4G Mobile, VoIP and Multimedia Infrastructures. For the customer-premises market, the Company offers interoperable connectivity solutions that provide a bridge between HDMI and DisplayPort and enable the distribution and presentation of high-definition (HD) content for consumer electronics, and personal computer markets. They also provide a family of communications processors that provide best-in-class performance for a range of applications.
The Company has more than 100 active customers. These customers include the leading global telecom equipment providers, semiconductor and consumer product companies.
In early November, TranSwitch announced that their HDplay™ TXC-44146 transceiver has been designed into Playvision's next generation high definition video switch targeted for production launch in December 2012. Playvision designs and manufactures high performance video equipment sold under leading brand names in Asia, Europe, and the Americas. By taking advantage of HDplay, Playvision is expanding their product offering to add DisplayPort™ support for their multimedia switching products. This enables users to connect next generation devices and quickly select between video sources.
Last week, TranSwitch announced financial results for the third quarter ended September 30, 2012. Net revenues for the third quarter of 2012 were approximately $4.8 million, compared to net revenues of $3.8 million for the second quarter of 2012 and $6.7 million for the third quarter of 2011. Net loss for the third quarter of 2012 was ($3.0) million, or ($0.09) per basic and diluted common share. This is in comparison to a net loss of ($6.0) million, or ($0.19) per basic and diluted common share for the second quarter of 2012, and a net loss of ($4.8) million, or ($0.16) per basic and diluted common share for the third quarter of 2011.
TranSwitch Corp. (TXCC), closed Thursday’s session at $0.8292, down 2.45%, on 182,478 volume with 248 trades. The average volume for the last 60 days is 114,970 and the stock's 52-week low/high is $0.777/$3.65.
PolyMedix, Inc. (PYMX)
Real Pennies and SmallCapVoice reported earlier on PolyMedix, Inc. (PYMX), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Radnor, Pennsylvania, PolyMedix, Inc. is a clinical stage biotechnology company that lists on the OTC Bulletin Board. The Company is developing a new class of antibiotics (defensin-mimetics) for the treatment of serious, life-threatening infections that often develop resistance to currently available antibiotics. The design of PolyMedix's compounds is to imitate the mechanism of action of host defense proteins, which contribute to natural human immunity. PolyMedix's compounds have been internally discovered using a proprietary drug design technology.
The design of the Company's lead antibiotic compound, brilacidin (formerly PMX-30063), is to exploit a method of bacterial cell killing, by way of biophysical membrane attack, against which bacteria have not shown development of resistance in multiple preclinical studies. Brilacidin showed efficacy similar to an active control. It was safely administered in a Phase 2 clinical trial in patients with acute bacterial skin and skin structure infections (ABSSSI) caused by Staph aureus bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)).
PolyMedix has plans to initiate a Phase 2B dose optimization study with brilacidin in ABSSSI patients. The Company also has plans to develop brilacidin as a topical treatment for oral mucositis.
The Company has internally developed a broad pipeline of compounds including other defensin-mimetic antimicrobial compounds for other infectious diseases such as Gram-negative pathogens, fungal infections, and malaria; PolyCides®, antimicrobial additives to materials to create self-sterilizing products and surfaces; and delparantag (formerly PMX-60056), an anticoagulant reversing agent.
Concerning Brilacidin (formerly PMX-30063) in patients with ABSSSI, PolyMedix's clinical team, together with Dr. Paul Ambrose and the Institute for Clinical Pharmacodynamics, completed their pharmacokinetic and pharmacodynamics (PK/PD) modeling. It analyzed the drug concentrations and clinical outcomes from the Phase 2 study and previous clinical and pre-clinical studies. This information was used to select doses for the planned Phase 2B study.
Based on the results of this analysis, the Company's plan is to study three brilacidin dosing regimens administering between 0.6 and 1.2 mg/kg over 1 to 3 days. The PK/PD modeling of the doses planned for the Phase 2B study predicts a high probability of efficacy and a low probability of blood pressure related adverse events. PolyMedix believes that a short course of antibiotic therapy could have significant advantages to patients, physicians, public health and payers.
PolyMedix, Inc. (PYMX), closed Thursday’s session at $0.08, up 19.40%, on 699,103 volume with 54 trades. The average volume for the last 60 days is 198,915 and the stock's 52-week low/high is $0.064/$1.50.
Pulse Electronics Corp. (PULS)
Street Insider and Wall Street Resources reported earlier on Pulse Electronics Corp. (PULS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Pulse Electronics Corp. is a company with a long operating history of innovation in magnetics, antennas and connectors, as well as the ability to ramp quickly into high quality, high-volume production. Pulse serves the wireless and wireline communications, power management, military/aerospace and automotive industries. The Company is a global leader in electronic component design and manufacturing. Pulse is a worldwide supplier of electronic components to OEMs, contract manufacturers and CEMs. The Company has their corporate headquarters in San Diego, California.
Pulse Electronics is a participating member of the IEEE, SFF, OIF, HDBaseT Alliance, CommNexus, and MoCA. Pulse has an extensive line of state-of-the-art catalog products as well as custom capabilities. The Company operates in three segments: Network, Power, and Wireless.
The Network segment produces a variety of passive components. These include connectors, filters, filtered connectors, transformers, inductors/chip inductors, splitters and diplexers, micro-filters, baluns, and chokes that manage and regulate electronic signals for use in diverse devices used in local area and wide area networks (LAN/WAN).
The Power segment mainly manufactures products that adjust and ensure current and voltage, limit distortion of voltage, sense and report current and voltage, and cause mechanical movement or actuation. Products include power and signal transformers, chokes, current and voltage sensors, automotive ignition coils, other automotive coils, inductors/chip inductors, military and aerospace products, as well as other power magnetic products.
The Wireless segment manufactures internal handset antenna and handset antenna modules, mobile and portable antennas, and antenna mounting components and cables that capture and transmit communication signals in handsets, other terminal and portable devices, automobiles and wireless-to-wireline access points.
Last week, Pulse Electronics reported results for their third quarter ended September 28, 2012. Net sales were $88.2 million, down 8.1 percent from $96.0 million in the prior-year quarter, and down 12.1 percent from $100.4 million in the second quarter.
Operating loss (U.S. GAAP) was $5.8 million compared with a loss of $0.7 million in the 2011 quarter and a loss of $0.1 million in the second quarter. Non-GAAP operating loss was $0.6 million, compared with a profit of $2.6 million in the 2011 quarter and a profit of $0.8 million in the second quarter.
Pulse Electronics Corp. (PULS), closed Thursday’s session at $0.38, even for the day, on 386,800 volume with 234 trades. The average volume for the last 60 days is 642,591 and the stock's 52-week low/high is $0.21/$3.30.
West Street Capital Corp. (WSC.V)
Today we are highlighting West Street Capital Corp. (WSC.V), here at the QualityStocks Daily Newsletter.
West Street Capital Corp. is an investment holding company that lists on the TSX Venture Exchange. The Company's investment portfolio consists principally of preferred shares, income trust units, as well as bonds. Their securities are classified as available-for-sale financial instruments. West Street Capital invests in different sectors. These include financial services, natural resources as well as real estate. The Company has their corporate headquarters in Toronto, Ontario.
West Street Capital was incorporated in 1984. The Company formerly went by the name Consolidated Enfield Corp. They changed their name to West Street Capital Corp. in May of 2004. West Street Capital holds an investment portfolio consisting of preferred share and debenture investments in a variety of Canadian and foreign corporations.
In late August 2012, West Street Capital reported net income for the quarter ended June 30, 2012 of $1.4 million. This net income is consistent with $1.4 million in the comparative quarter in the prior year. The Company had reported net income for the quarter ended March 31, 2012 of $1.5 million.
After providing for unpaid preferred share dividend obligations of $0.7 million (2011 - $0.7 million) that accumulated during the quarter ended June 30, 2012, net income per common share was $0.06 for the period ended June 30, 2012 (2011 - $0.06).
Comprehensive income for the Company, which includes both net income and other comprehensive income, for the quarter ended June 30, 2012, totaled $6.5 million. This is in comparison to $3.7 million in the comparative period in the prior year. This reduced the common share deficit to $25.3 million. West Street Capital reported comprehensive income for the three months ended March 31, 2012 of $7.1 million.
West Street Capital recorded an unrealized gain of $5.2 million (2011 - $2.3 million) because of increases in the fair value of the securities portfolio which is recorded in other comprehensive income.
West Street Capital Corp. (WSC.V), closed Thursday’s session at $0.25, up 35.14%, on 3,000 volume. The stock's 52-week low/high is $0.13/$0.45.
American Power Group Corp. (APGI)
Today we are highlighting American Power Group Corp. (APGI), here at the QualityStocks Daily Newsletter.
Founded in 1992, American Power Group Corp. is a designer and producer of proven alternative fuel solutions. These solutions are for stationary power generators, backup power systems and commercial transportation. The Company's alternative energy subsidiary, American Power Group, Inc., provides a cost-effective patented Turbocharged Natural Gas™ conversion technology for aftermarket vehicular, stationary and off-road mobile diesel engines.
The Company formerly went by the name GreenMan Technologies, Inc. They changed their name to American Power Group Corp. in July 2012. The Company has their headquarters in Lynnfield, Massachusetts. Their shares trade on the OTCQB.
American Power, through the science of combustion, creates dual fuel systems. These proprietary solutions supply a blend of economical natural gas alternatives and diesel specifically harmonized to the unique specifications of commercial diesel engines. The Company's dual fuel systems use as much as 50 percent low cost natural or methane gas content.
American Power Group's dual fuel technology is a non-invasive energy enhancement system. It converts existing diesel engines into more efficient and environmentally friendly engines that have the flexibility to run on diesel fuel and liquefied natural gas; diesel fuel and compressed natural gas; diesel fuel and pipeline or wellhead gas; and diesel fuel and bio-methane. It has the flexibility to return to 100 percent diesel fuel operation at any time.
Methane gas is metered into a diesel engine's air intake, before the turbocharger, by the air filter. As the enriched air/gas mixture increases the engine's power, the diesel's own governor senses the power increase and backs off on diesel flow. The Company's system maintains a balance of gas-to-diesel ratios, (approximately 80-50 percent natural gas to 20-50 percent diesel fuel) keeping the proper BTU energy within the engine across its power curve.
Last month, American Power Group announced that their subsidiary, American Power Group, Inc. (APG) received orders for vehicular dual fuel conversions valued at over $500,000. These orders were received from several certified dealers and customers who intend to install APG's dual fuel system on 42 heavy-duty trucks. The certified dealers intend to distribute these dual fuel trucks to more than 30 prospective customers so that they may evaluate the costs savings and benefits of APG's V5000 Dual Fuel Turbocharged Natural Gas™ System.
American Power Group Corp. (APGI), closed Thursday’s session at $0.56, down 3.45%, on 53,900 volume with 27 trades. The average volume for the last 60 days is 74,110 and the stock's 52-week low/high is $0.12/$0.89.
Axxess Unlimited [Azia Corp.] (AXXU)
Today we are highlighting Axxess Unlimited [Azia Corp.] (AXXU), here at the QualityStocks Daily Newsletter.
Axxess Unlimited (Azia Corp.) is an emerging data flow management and digital marketing company. Axxess Unlimited has two divisions: data flow management and proprietary digital marketing platforms. The Company has their headquarters in Scottsdale Arizona, with offices in Los Angeles, California and Las Vegas, Nevada. Their shares trade on the OTC Pink Current Information.
Axxess Unlimited's lead data flow management product, Axxess Information Reporting (AIR), currently processes data from breath alcohol ignition interlock devices (IIDs), which are used by the court system to prevent people from starting their cars if they have been drinking. Developed and patented by Mr. Michael Roth, a retired Arizona city court judge, AIR currently processes more than 48,000 data logs annually to courts, probation offices and state agencies on behalf of interlock distributors and manufacturers.
Axxess Unlimited's digital marketing division blends strategy, creative services, technology, media, and data offerings to connect brands with their target markets in ways that provide rapid growth in sales and profits. The Axxess Ad Tracker, launched in May of 2012, leads the digital marketing platform. Ad Tracker is the first acquisition-focused ad tracking technology that allows companies to track responses across multiple advertising mediums. This helps them to optimize marketing expenditures and effectively increase profits.
The Company's tightly integrated proprietary technology platform enables companies to manage all of their digital marketing efforts easily, including referral programs and extensive social media - while reaching, engaging and learning about their customers. Their clients include World Series of Fighting (WSOF), Pet Club, International Modeling & Talent Association, and Michelle Cosmetics.
Yesterday, Axxess Unlimited (Azia Corp.) announced that they launched their first ignition interlock mobile application, the Axxess Information Reporting (AIR) app. It is now available through Apple for the iPhone and iPad.
The Axxess Information Reporting (AIR) app has an intuitive interface and up-to-date information. The application includes a breath alcohol calculator (BAC) to help those with an interlock to not violate their restricted driving privilege. It also includes a sales and service locator, the Company's "Connect to Cab" feature, and Axxess' previously announced "Refer a Friend" portal, which helps distributors and manufacturers enhance their marketing effort by allowing app users to generate income for themselves and interlock companies by referring potential new clients.
Axxess Unlimited [Azia Corp.] (AXXU), closed Thursday’s session at $1.24, up 16.98%, on 1,010,785 volume with 731 trades. The average volume for the last 60 days is 2,444 and the stock's 52-week low/high is $1.02/$1.42.
Lorus Therapeutics, Inc. (LOR.TO)
We are highlighting Lorus Therapeutics, Inc. (LOR.TO), here at the QualityStocks Daily Newsletter.
Lorus Therapeutics, Inc. is a biopharmaceutical company whose shares trade on the Toronto Stock Exchange. The Company specializes in the discovery, research and development of pharmaceutical products and technologies for the management of cancer. The Company's goal is to capitalize on their research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to manage cancer successfully. In addition, Lorus Therapeutics has expertise in antimicrobial drug discovery. The Company is based in Toronto, Ontario.
Lorus' active pipeline has product candidates in different anticancer therapies. These include small molecule therapies based on anti-proliferative and anti-metastatic properties. These also include immunotherapy, based on stimulating anticancer properties of the immune system and direct cytotoxicity. The Company has expertise in RNA-targeted therapies (antisense and siRNA) based on synthetic segments of DNA or RNA designed to bind to the messenger RNA that is responsible for the production of proteins over-expressed in cancer cells. Their lead antisense program is Phase III-ready and available for partnering.
One of the Company's products is IL-17E (also known as IL-25). A recently identified cytokine, it plays an important role in inflammation. Lorus has discovered that human IL-17E has potent anticancer properties against a range of solid tumors, including human melanoma, pancreatic, colon, lung, ovarian and breast tumor models with very low toxicity.
In late August, Lorus Therapeutics announced that the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) awarded funding to the Company to support development of IL-17E for cancer therapy. The $50,000 non-repayable contribution from NRC-IRAP will be used for a pilot development project to manufacture IL-17E. The project will be carried out by researchers at the National Research Council. These researchers have extensive experience in the development, recovery and purification of recombinant proteins and peptides produced by different expression systems.
The NRC-IRAP support will allow Lorus Therapeutics to access state-of-the art knowledge and capabilities combined with the required technical equipment. The intention of this project is to provide technical manufacturing development and pilot scale production for IND-enabling studies in support of larger scale production of IL-17E for cancer clinical trials.
Recently, Lorus Therapeutics reported financial results for the three months ended August 31, 2012. Net loss for the three months ended August 31, 2012 was $1.3 million ($0.03 per share) compared with $1.1 million ($0.06 per share) during the same period in fiscal 2012. Increased research and development expenditures of $69,000 due to increased activity as the Company's IL-17E program gets underway and the LOR-253 Phase I clinical trial moves towards completion, as well as higher general administrative expenses of $72,000 offset by lower accounting costs, resulted in the overall increase in net loss during the quarter.
Lorus Therapeutics, Inc. (LOR.TO), closed Thursday’s session at $0.32, up 6.67%, on 4,216 volume. The stock's 52-week low/high is $0.16/$0.64.
Pacific WebWorks, Inc. (PWEB)
FeedBlitz, CoolPennyStocks, BullRally, Stock Rich, HotOTC, Hotstocked, MicrocapVoice, and Greenbackers reported previously on Pacific WebWorks, Inc. (PWEB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Salt Lake City, Utah, Pacific WebWorks, Inc. provides a comprehensive suite of affordable, easy-to-use software programs. These programs are for small businesses that desire to create, manage, and maintain an effective Web strategy including full e-commerce capabilities. The Company formed in 1999 due to a merger between Utah WebWorks, Inc. and Asphalt Associates, Inc. Pacific WebWorks' Visual WebTools product has helped many individuals to operate businesses on the internet over the years. The Company's shares trade on the OTC Bulletin Board.
Pacific WebWorks operates several wholly owned subsidiaries. These include Intellipay, their Internet gateway, TradeWorks Marketing, Headlamp Ventures and others. Intellipay engages in the credit card transaction processing business. They are a leading developer and provider of trusted, proprietary, high-quality transaction processing and payment products for all businesses.
The Company's Visual WebTools™ Software gives a user everything they require to create and manage a business on the Internet. The Visual WebTools™ Suite includes WebWizard™, WebChannels, ClipOn Commerce, Profiler, WebContacts, and WebStats. Pacific WebWorks businesses also include Asher Gloves, Thrifty Seeker, Headlamp Ventures, and ClipOn Commerce.
This week, Pacific WebWorks announced that their longtime Chairman and Chief Executive Officer (CEO), Mr. Kenneth W. Bell, intends to retire effective November 30, 2012. Mr. Bell has served as the CEO of Pacific WebWorks since joining the Company in January 2001 and as Chairman since March 2001. Company President Mr. K. Lance Bell has been appointed as the new Chairman and CEO, effective December 1, 2012. Mr. Bell has served as President of Pacific WebWorks since May 2011.
In addition, Pacific WebWorks announced that Mr. James C. Roundy would be appointed as Vice President of Sales and Marketing. He will fill a seat on the Company's Board of Directors. Additionally, Mr. Tanner J. Purser will be appointed as Controller and Secretary to the Board of Directors.
Pacific WebWorks, Inc. (PWEB), closed Thursday’s session at $0.006, up 30.43%, on 10,000 volume with 1 trade. The average volume for the last 60 days is 14,078 and the stock's 52-week low/high is $0.001/$0.034.
DoMark International, Inc. (DOMK)
The QualityStocks Daily Newsletter would like to spotlight DoMark International, Inc. (DOMK). Today, DoMark International, Inc. closed trading at $0.40, up 6.70%, on 774,647 volume with 246 trades. The stock’s average daily volume over the past 60 days is 69,245, and its 52-week low/high is $0.32/$4.88.
DoMark International, Inc. wholly-owned subsidiary, SolaWerks, Inc., reported obtaining exclusive rights today to game-changing infrared light technology that will add mightily to the subsidiary's primary lineup of products featuring the SolaPad™ and SolaCase™, combined cover/charging systems for Apple's iPad and iPhone, adding infrared light to the capture spectrum these devices derive charging power from. It is getting easier than ever to charge mobile devices and SolaWerks has hereby captured one of the most compelling solutions, a contained cover for the device(s) which allows for capturing ambient visible light energy (and now the infrared light spectrum). The infrared spectrum makes up some 47% of the Sun's overall light output and the failure to commercially harness this huge source is about to change big time, allowing users to help double Apple device battery life.
DoMark International, Inc. (DOMK) is focused on researching, evaluating, and acquiring profitable private firms in the business segments of sports, technology, medical, energy, and business services. By providing the financial and human capital necessary to deal with overwhelming administrative, planning, governance, compliance, and regulatory challenges, its newly acquired partners can focus their energy and flourish.
Through its wholly owned subsidiary, SolaWerks, Inc., DoMark is committed to revolutionizing the efficiency and capabilities of a new generation of mobile devices. The subsidiary's current focus is on developing and distributing the SolaPad, a combined cover and charging system for Apple's iPad, and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone.
Musclefoot, Inc., another wholly owned subsidiary of DoMark, is engaged in the distribution, marketing, and sale of Barefoot Science, the revolutionary patented foot care system designed to relieve foot and back pain as well as improve athletic performance. With a strong commitment to customer service and security, DoMark plans to expand its marketing relationships across a far broader product set.
The management team has positioned the company to capitalize on emerging opportunities by working with the world's most forward-thinking companies to develop and market game-changing products with the promise of long-term financial growth. Leveraging the expertise of its team, the company continues to evaluate acquisition candidates and products targeting underserved markets to increase its growth potential. Disclaimer
DoMark International, Inc. Blog
DoMark International, Inc. News:
SolaWerksTM Extending Lead in Mobile Energy by Adding Infrared to Its Solar Powered Apple Accessory Products
DoMark Subsidiary SolaWerks Next Generation Technology Slated for Release
Hot on the Heels of the Freshly Launched Apple Mini Tablet, SolaWerks Prepares to Unveil the Ultimate Apple Accessory - the Latest SolaCase
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $9.00, up 0.11%, on 36,953 volume with 93 trades. The stock’s average daily volume over the past 60 days is 47,143, and its 52-week low/high is $0.85/$10.01.
TNI BioTech Inc. announced signing an exclusive distributor agreement today to provide IRT-103 LDN and IRT-104 LDN cream (developed as a treatment for cancer, HIV/AIDS and other autoimmune diseases) for a major consortium of management consultant, general pharmaceutical, clinical pharmacy, and marketing executives (each a 25-year or more industry veteran) in the Federal Republic of Nigeria, G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC. CEO of TNIB, Noreen Griffin, called it a clear sign to shareholders of TNIB's aggressiveness towards generating revenue during the company's first year of operations and hailed the exclusive marketing and distribution rights for the products as a real boon for TNIB. G-Ex/St.Maris will provide a revolving letter of credit for the minimum purchase of 750k doses (at $1.00/dose) monthly of IRT-103 LDN or IRT-104 LDN cream beginning March 1, 2013.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.40, even with yesterday's close. The stock’s average daily volume over the past 60 days is 6,148, and its 52-week low/high is $0.35/$1.87.
GlobalWise Investments, Inc. reported financial results today for the third quarter and nine months ending September 30, 2012, with such highlights as a 15% jump in revenues to over $711k, increase in gross profit margin by 4%, gross profits up 23% to just over $484k, and no material change in operating expenses.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Reports Third Quarter 2012 Financial Results and Provides Revised Fiscal 2012 Guidance
GlobalWise Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
GlobalWise Announces New Channel Partnership With Level Seven
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.185, even for the day, on 139,248 volume with 27 trades. The stock’s average daily volume over the past 60 days is 115,134, and its 52-week low/high is $0.144/$0.69.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch
International Stem Cell Corp Announces Third Quarter 2012 Financial Results
International Stem Cell Corporation to Host Third Quarter 2012 Financial Results Conference Call at 11:00 a.m. ET on Friday, November 9, 2012
SolaWerks, a subsidiary of DoMark International, today announced acquisition of exclusive rights to revolutionary, patent pending technology that harnesses infrared light to charge mobile devices. SolaWerks, which already markets solar powered covers/chargers designed to be used with Apple (NASDAQ: AAPL) devices, will now be able to add infrared light as a charging source in all of its products.
Solar technology has been primarily concerned with the visible light spectrum, which accounts for only 7% of the light emitted by the sun. According to today’s press release, infrared light, the most abundant of the sun’s light spectrum (accounting for 47% of the sun’s light), has not been commercially harnessed as an energy source to date. This light comes from many readily available light sources other than the sun, including incandescent light, the clouds (through re-reflection), and even the Earth itself. By capturing infrared light, millions will finally be able to achieve a truly wireless world as devices would no longer need to be plugged in to charge.
SolaWerks covers/chargers enhanced with infrared capability will help double Apple device battery life using on-board battery back-up that maintains a charge with ambient light. “To date, over 200 samples of the new product have undergone beta testing by existing SolaWerks customers, third party testers, and staff. SolaWerks has taken into consideration voluminous feedback from many current users in bringing its next generation products to market. The response from our demo group has been nothing short of exceptional. We are very pleased,” stated Andy Ritchie, CEO of DoMark.
The SolaCaseTM and SolaPadTM systems cover and recharge the batteries of Apple’s iPhone and iPad devices using solar power. Each cover contains a large, high-efficiency solar panel on its reverse side, plus an internal battery to keep Apple devices charged at all times. SolaWerks technology promises liberation from having to charge devices for hours in order to get full-day performance.
According to ABI Research, the Apple accessory market, dubbed the “Apple Economy,” accounted for $5-$6 billion of the estimated $34 billion 2011 global mobile device accessory market. Andy Ritchie commented: “With the Apple iPhone 5 launch, undoubtedly the most impressive iPhone to date, we have been busier than ever.”
For more information on SolaWerks or to learn more about SolaWerks products, visit www.solawerks.com
Today, shortly before the opening bell, TNI BioTech announced that it has signed an exclusive distributor agreement with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC for the Federal Republic of Nigeria. As a result, G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC will have exclusive marketing and distribution rights to IRT-103 LDN and IRT-104 LDN cream in Nigeria. TNIB will be responsible for the manufacture and supply of IRT-103 LDN and IRT-104 LDN cream.
The therapies, developed as a treatment for cancer, HIV/AIDS, and other autoimmune diseases, are to be manufactured in the company’s facility in Managua, Nicaragua, under the supervision and quality control of Dr. Henry “Skip” Lenz. G-Ex Technologies/St. Maris Pharma have agreed to provide TNIB with a revolving letter of credit for the minimum purchase of 750,000 doses monthly of IRT-103 LDN or IRT-104 LDN cream beginning March 1, 2013, priced at $1.00 dollar per dose.
Under the terms of the agreement, G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC must purchase a minimum of 15,000,000 doses monthly within 24 months to maintain their exclusive agreement. Once G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC reach sales of 1,000,000 million doses per day, TNIB has agreed to joint venture a factory in the Federal Republic of Nigeria to meet local demands.
Noreen Griffin, CEO of TNI BioTech, Inc. stated, “This contract shows TNI BioTech’s commitment to generate revenue during our first year of operations.”
Frank Aribeana, the managing member of G-Ex Technologies/St Maris Pharma, commented, “We are delighted to enter into this agreement as we believe the introduction of IRT-103 LDN and IRT-104 LDN cream in this market will allow us to provide much needed treatment at an affordable price to the citizens of the Federal Republic of Nigeria.”
G.Ex Technologies/St. Maris Pharma is comprised of management consultant, general pharmaceutical, clinical pharmacy, and marketing executives, each with more than two decades of industry experience and well versed in the changing dynamics of the prescription and OTC drug international marketplace. Actively supported by medical practice professionals in business and academia who have been involved in the management of related drug therapies for many years, the consortium is well positioned to lead the successful introduction of IRT-103 LDN and IRT-104 LDN in Nigeria.
For more information on TNI Biotech, visit www.tnibiotech.com
GlobalWise Investments and its wholly owned subsidiary Intellinetics, an enterprise content management (“ECM”) software development, sales, and marketing company, just announced financial results for the third quarter and nine months ended September 30, 2012.
Financial Highlights for the quarter include:
o Total revenue increased by 15% to $711,737 compared to $617,026 in the year-ago third quarter;
o Gross profit improved to $484,205, a 23% increase over the year-ago third quarter of $395,104;
o Gross profit margin increased to 68% compared to 64% in the year-ago third quarter;
o Operating expenses, excluding non-recurring and non-cash expenses totaling $206,800, increased to $682,976 from $438,821 in the year-ago third quarter; and
o Adjusted EBITDA (as defined below) for the third quarter was ($192,034) compared to ($34,569) in the year-ago third quarter.
Financial Highlights for the nine-month period include:
o Total revenue increased 36% to $1,959,350 compared to $1,438,203 in the year-ago nine month period;
o Gross profit improved by 43% to $1,137,709 compared to $794,748 in the year-ago nine month period;
o Gross profit margin increased to 58% compared to 55% in the year-ago nine month period;
o Operating expenses, excluding non-recurring and non-cash expenses totaling $987,800, increased to $1,730,945 compared to $1,228,510 in the year-ago nine month period; and
o Adjusted EBITDA (as defined below) for the nine months ended September 30, 2012, was ($572,062) compared to ($403,481) in the year-ago nine month period.
“Excluding non-recurring and non-cash charges, our operating expenses were materially unchanged in the third quarter 2012 vs. the second quarter 2012 at around $680,000,” stated William J. “BJ” Santiago, CEO of GlobalWise. “We expect operating expenses to remain relatively stable at current levels as revenue increases. We’re seeing a continued increase in channel partner sales activity and are currently on track to achieve steady revenue growth in the fourth quarter.”
GlobalWise also provided investors with revised fiscal year 2012 guidance. Based on its current sales funnel and recent channel partner activity, the company currently anticipates annual revenue for the year to be in the range of $2.8 million to $3.3 million.
For more details on the company’s recent financial performance, view the full press release posted on the GlobalWise website at www.globalwiseinvestments.com/globalwise-reports-third-quarter-2012-financial-results-and-provides-revised-fiscal-2012-guidance
For additional information on the company, visit www.GlobalWiseInvestments.com
Alimera Sciences, a biopharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals, announced that it has appointed the management team that will oversee European commercialization of its lead product, ILUVIEN®. Philip Ashman, Ph.D., has been appointed senior vice president and European managing director, while Eric Teo, MBBS, will serve as vice president and European medical director with Anne-Marie swift serving as vice president and European marketing director.
Dan Myers, president and chief executive officer, Alimera, said, “I am delighted to welcome these talented individuals to Alimera. We believe their broad pharmaceutical experience, and knowledge of the European ophthalmic market, will be integral to achieving our goal of a successful launch of the product in Europe. We are confident in this team’s ability to drive not only European sales of ILUVIEN in our initial launch markets, but also the development of our long term strategy in Europe.”
Dr. Ashman holds over 20 years of experience in all aspects of pharmaceutical management, experience that will be an asset to Alimera. Throughout his career Dr. Ashman has held several leadership roles, including serving as vice president at Bayer, where he was responsible for defining strategy and setting early preparations for specialty medicines. During his tenure at Bayer, Dr. Ashman also served as Regional Business Unit Head (Europe) in Oncology, where he oversaw the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East, and Africa. Most recently, Dr. Ashman has been responsible for leadership of the market access strategy in the U.K. for Bayer, during which time he covered numerous therapy areas including ophthalmology. Dr. Ashman’s qualifications include a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., as well as a Bachelor of Science degree in biochemistry from the University College London, U.K.
Eric Teo, MBBS, MBA, FFPM, FRCP, LLM, following a career as a physician, moved to the pharmaceutical industry where he has worked for over 11 years in assorted roles in medical and regulatory affairs where he most recently served as director of global regulatory affairs, health, and personal care for Reckitt Benckiser. Teo also established the European medical and regulatory team following Benckiser’s acquisition of Boots Healthcare, leading several successful European product launches in the process. Dr. Teo received training as physician at the University of Melbourne, Australia, and is a Fellow of the Royal College of Physicians and Surgeons (Glasgow) and a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, U.K. Additionally, Dr. Teo obtained a MBA from London Business School as well as a LLM from BPP Law School, London.
Anne-Marie Swift, trained as a registered nurse, has worked extensively as a senior market leader in ophthalmic pharmaceuticals. Prior to joining Alimera, Ms. Swift worked at Pfizer Limited as a European brand director of ophthalmology, where she focused on glaucoma and retina treatments. As director of ophthalmology, Swift was responsible for the management of all aspects of marketing — including development of the medical education programs and key opinion leaders — for Xalatan® and Xalacom® throughout Europe. Ms. Swift holds a registered general nursing (RGN) degree from St. Helens and Knowsley School of Nursing, Merseyside, a renal and urology specialist nursing degree from Oxford School of Nursing, Oxford, and a Bachelor of Arts in health studies from Oxford Brookes University.
“ILUVIEN is the first sustained release treatment option for the many patients in Europe suffering from chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. It is a very exciting time to be joining Alimera Sciences and to have the opportunity to lead the commercial launch of this brand in Europe,” noted Dr. Ashman. “This is a significant step for the company and the many patients with chronic DME.”
Today's Top 3
Penny Stock Beats
Investor News Source
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
- GreeneStone Healthcare Corp. (GRST) Seeks Amex Listing - New Report Confirms Demand
- International Stem Cell Corp. (ISCO) Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs
- Loans4Less.com, Inc. (LFLS) Provides Preliminary Financial Results for the Third Quarter of 2012
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- TNI BioTech Inc. (TNIB) and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
- VistaGen Therapeutics, Inc. (VSTA) Completes $3.25 Million Financing and $3.0 Million Debt Restructuring